Vivotif® -: A 'magic shield' for protection against typhoid fever and delivery of heterologous antigens
Vivotif® -: A 'magic shield' for protection against typhoid fever and delivery of heterologous antigens
复制标题
DOI：
10.1159/000100515
复制
发表时间：
2007-01-01
期刊：
影响因子：
3.3
通讯作者：
Dietrich, Guido
中科院分区：
文献类型：
--
作者：
Gentschev, Ivaylo;Spreng, Simone;Dietrich, Guido
减毒伤寒沙门氏菌菌株Ty21a是Vivotif（（R））的主要成分，Vivotif是唯一的减毒伤寒活口服疫苗。与抗生素相比，抗生素是保罗埃利希为治疗传染病而努力的“灵丹妙药”，这种疫苗应该被视为“魔法盾牌”，因为用这种疫苗株免疫不是在感染开始后治疗伤寒，而是通过诱导特异性免疫反应来预防感染和疾病。Ty21a也是用于递送异源抗原的有吸引力的载体。最近，我们成功地使用Ty21a通过大肠杆菌的溶血素分泌系统进行抗原递送，这允许从载体细菌有效地分泌蛋白质。版权所有（c）2007 S. Karger AG，巴塞尔
The attenuated Salmonella typhi strain Ty21a is the main constituent of Vivotif((R)), the only attenuated live oral vaccine against typhoid fever. In comparison with antibiotics, the 'magic bullets' which Paul Ehrlich was striving for to treat infectious diseases, this vaccine should be viewed as a 'magic shield', because rather than treating typhoid fever after the infection has started, immunisation with this vaccine strain prevents infection and disease by the induction of specific immune responses. Ty21a is also an attractive carrier for the delivery of heterologous antigens. Recently, we successfully used Ty21a for antigen delivery via the haemolysin secretion system of Escherichia coli, which allows efficient protein secretion from the carrier bacteria. Copyright (c) 2007 S. Karger AG, Basel